预约演示
更新于：2025-05-16
Famotidine
法莫替丁
更新于：2025-05-16
概要
基本信息
简介法莫替丁是一种药物，可以帮助患有胃炎和消化性溃疡等胃病的人。它属于一组称为 H2 受体拮抗剂的药物，其作用是阻止胃产生过多的酸。当胃酸过多时，人们会感到很痛，如胃灼热或消化不良。法莫替丁真的很擅长减少胃酸，让人感觉更好。它有不同的形式，如药片和注射剂，因此人们可以选择最适合自己的方式。 Bausch Health Americas 于 1986 年生产了法莫替丁，此后被很多人使用。人们应该确保按照医生的指示服用法莫替丁，以确保其正常工作并避免任何副作用。 |
药物类型 小分子化药 |
别名 (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide、3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide、3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine + [40] |
作用方式 拮抗剂 |
作用机制 H2 receptor拮抗剂(组胺H2受体拮抗剂) |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H15N7O2S3 |
InChIKeyXUFQPHANEAPEMJ-UHFFFAOYSA-N |
CAS号76824-35-6 |
关联
146
项与 法莫替丁 相关的临床试验NCT06507904
A Phase 1, Randomized, Crossover Design Study to Assess Palatability of Osivelotor (PF-07940367) Pediatric Formulations With Dosing Vehicle (Part 1) and Randomized, Single-Dose, Parallel Design Study to Estimate Relative Bioavailability of Osivelotor Pediatric Formulation With Dosing Vehicle and With Water Compared to Clinical Tablet Formulation, and Effect of Food and/or Acid-Reducing Agent On Bioavailability In Healthy Adult Participants (Part 2)
NCT06819670
A Multicenter Pilot Clinical Trial to Prevent Infantile Spasms Relapse
NCT06801626
Novel Strategies for Reducing Burn Scar Itch
100 项与 法莫替丁 相关的临床结果
登录后查看更多信息
100 项与 法莫替丁 相关的转化医学
登录后查看更多信息
100 项与 法莫替丁 相关的专利（医药）
登录后查看更多信息
4,564
项与 法莫替丁 相关的文献（医药）2026-04-01DEN open
Olmesartan‐induced gastritis with no lower gastrointestinal symptoms: A case report
Article
作者: Kamiyama, Miki ; Ochi, Masahiro ; Kosaka, Satoshi
Abstract:
A 74‐year‐old man with decreased appetite, weight, and heartburn was referred to our hospital. His medications included olmesartan. Esophagogastroduodenoscopy (EGD) revealed antral‐dominant erosive gastritis and nodular mucosa. A gastric biopsy revealed inflammatory cell infiltration. The serum anti‐Helicobacter pylori immunoglobulin G antibody test result was negative. Famotidine was ineffective in relieving his symptoms, and esomeprazole failed to prevent overt gastric bleeding, which required endoscopic hemostasis. The working diagnosis was drug‐induced gastritis, particularly olmesartan‐induced gastritis. His appetite loss started to improve within a week of olmesartan withdrawal. The erosions healed on EGD 2 months later. Over the next 10 months, he remained in his usual state until olmesartan was inadvertently administered. Subsequent EGD revealed a mild gastritis relapse. We diagnosed olmesartan‐induced gastritis and discontinued olmesartan treatment. Mucosal healing was confirmed by EGD 1 year later. Olmesartan is known to cause angiotensin II receptor blocker‐induced enteropathy. Although angiotensin II receptor blocker‐induced enteropathy affects the stomach, angiotensin II receptor blocker‐induced gastritis without lower gastrointestinal symptoms is rare. The characteristic endoscopic appearance may provide a clue to the correct diagnosis.
2025-07-01JOURNAL OF PEDIATRICS
Features Associated with Response to Tonsillectomy in Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis Syndrome in Children
Article
作者: Romeo, Tina ; Manthiram, Kalpana ; Failla, Laura ; Ombrello, Amanda ; Mudd, Pamela ; Edwards, Kathryn M ; Ortega-Villa, Ana M ; Srinivasalu, Hemalatha ; Barron, Karyl ; Bowes, Mary ; Kastner, Daniel L ; Garguilo, Kathryn ; Lapidus, Sivia
OBJECTIVE:
To identify clinical features associated with response to tonsillectomy among children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome and to determine optimal management of children with continued episodes after tonsillectomy.
STUDY DESIGN:
Patients with PFAPA seen at Vanderbilt University Children's Hospital and the National Institutes of Health (NIH) who underwent tonsillectomy were enrolled and queried regarding symptoms before and after surgery.
RESULTS:
Ninety-seven subjects with PFAPA (43 Vanderbilt, 54 NIH) were followed for a median of 49 months following tonsillectomy. Nearly half of participants reported complete resolution of PFAPA episodes (65% at Vanderbilt and 35% at NIH), while 25% had less severe or frequent episodes, 23% had a period of remission with recurrence, and 4% had no change in episodes. By logistic regression, factors associated with a full response to tonsillectomy were episode resolution with glucocorticoid treatment, presence of exudative pharyngitis, absence of rash, and absence of arthralgia/myalgia during pre-tonsillectomy PFAPA flares. Among those requiring treatment for persistent flares post-tonsillectomy, 15/19 (79%) reported improvement with cimetidine or famotidine prophylaxis.
CONCLUSION:
Tonsillectomy remains effective in improving PFAPA flares in most patients. However, unique episode features prior to tonsillectomy appear to be clinical predictors of response to tonsillectomy. Histamine receptor 2 antagonists like cimetidine were effective prophylactic agents for refractory cases post-tonsillectomy. Patients with incomplete response to tonsillectomy may represent a subset of PFAPA with unique factors affecting their pathogenesis.
2025-05-01CLINICAL PHARMACOLOGY & THERAPEUTICS
Clinical Evaluation of Drug–Drug Interactions with Obeldesivir, an Orally Administered Antiviral Agent
Article
作者: Amini, Elham ; Winter, Helen ; Llewellyn, Joe ; Chen, Shuguang ; Peng, Chi‐Chi ; Xiao, Deqing ; Lichtman, Amos ; Stacom, Caitlin ; Kwan, Anna ; Mak, Lily ; Raut, Anuja ; Humeniuk, Rita ; Koullias, Yiannis ; Madera, Sharline ; Caro, Luzelena ; Davies, Santosh
Obeldesivir is an oral nucleoside analog prodrug inhibitor of SARS‐CoV‐2 RNA‐dependent RNA polymerase and other viral polymerases. Here, two Phase I studies evaluated potential drug–drug interactions between obeldesivir and substrates or inhibitors of cytochrome P450 and drug transporters in healthy participants. When obeldesivir was tested as a precipitant, pharmacokinetic parameter point estimates for midazolam (CYP3A4 inhibition/induction), caffeine (CYP1A2 inhibition), and metformin (organic cation transporter 1 inhibition) exposures were within 80–125% no‐effect bounds representing the interval within which a systemic exposure change does not warrant clinical action based on EMA/FDA guidance. Dabigatran (P‐glycoprotein substrate) and pitavastatin (organic anion transporting polypeptide 1B1/1B3 substrate) exposures decreased by approximately 25% and 30%, respectively, with obeldesivir coadministration; these were considered not clinically relevant, as these exposure changes are not associated with dose changes or precautions in the US prescribing information for these drugs. When obeldesivir was evaluated as an object, exposures of GS‐441524, the parent nucleoside metabolite of obeldesivir, were within the 80–125% no‐effect bounds for ritonavir (P‐glycoprotein inhibition) and cyclosporin A (breast cancer resistance protein inhibition) coadministration [Correction added on 7 February 2025, after first online publication: The word monophosphate has been removed in this version.]. Famotidine (gastric acid suppression) coadministration decreased GS‐441524 exposure by approximately 26%; this was within the range of exposures observed in previous Phase III studies and was considered not clinically relevant. Obeldesivir was well tolerated, and adverse events were mild to moderate. These findings indicate that obeldesivir has low potential for drug–drug interactions. Obeldesivir remains a promising treatment against a broad spectrum of viruses given its antiviral activity and favorable safety profile.
100 项与 法莫替丁 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 食管溃疡 | 澳大利亚 | 2003-04-08 | |
| 急性胃炎 | 日本 | 2000-03-15 | |
| 吻合口溃疡 | 日本 | 2000-03-15 | |
| 慢性胃炎 | 日本 | 2000-03-15 | |
| 反流性食管炎 | 日本 | 2000-03-15 | |
| 出血性胃炎 | 日本 | 2000-03-15 | |
| 胃溃疡 | 日本 | 2000-03-15 | |
| 应激性溃疡 | 日本 | 2000-03-15 | |
| 上消化道出血 | 日本 | 2000-03-15 | |
| 消化道出血 | 中国 | - | 1996-01-01 |
| 胃炎 | 日本 | 1988-12-27 | |
| 消化性溃疡 | 日本 | 1988-12-10 | |
| 角膜溃疡 | 美国 | 1986-10-15 | |
| 十二指肠溃疡 | 美国 | 1986-10-15 | |
| 食管炎 | 美国 | 1986-10-15 | |
| 良性胃溃疡 | 美国 | 1986-10-15 | |
| 胃食管反流 | 美国 | 1986-10-15 | |
| 多发性内分泌瘤病 | 美国 | 1986-10-15 | |
| 溃疡 | 美国 | 1986-10-15 | |
| Zollinger-Ellison综合征 | 美国 | 1986-10-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非糜烂性胃食管反流病 | 临床3期 | 日本 | 2005-09-01 | |
| HIV血清阳性 | 临床1期 | - | 2008-06-01 | |
| 胃灼热 | 临床1期 | - | 2006-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 72 | Adjuvant RT+Nivolumab (Single Modality De-escalation Arm (SDA)) | 鹹膚獵觸構襯糧鹽憲膚 = 廠鏇衊積齋鏇鏇遞鑰繭 艱襯艱鑰鹹顧繭餘廠觸 (築憲餘鏇獵遞糧鑰齋憲, 積膚壓壓廠餘範夢鏇憲 ~ 餘鹹製糧繭製衊蓋選簾) 更多 | - | 2025-05-06 | ||
Chemoradiotherapy+Nivolumab+Paclitaxel+Hydroxyurea+cisplatin+Famotidine+Diphenhydramine+Dexamethasone+5-FU (Intermediate De-escalation Arm (IDA)) | 鹹膚獵觸構襯糧鹽憲膚 = 壓鹽淵鏇築憲糧膚膚構 艱襯艱鑰鹹顧繭餘廠觸 (築憲餘鏇獵遞糧鑰齋憲, 艱糧餘築淵膚齋遞網觸 ~ 網衊糧鬱鏇遞顧夢築繭) 更多 | ||||||
临床2期 | 80 | (Famotidine) | 鑰糧襯遞艱積範廠簾壓(網餘衊積壓糧糧鏇淵鹹) = 醖襯淵憲廠鬱鬱築糧構 餘醖膚淵範願繭鹽淵鑰 (築艱廠蓋積鏇艱醖繭蓋, 蓋鑰觸壓鹹觸齋鑰鏇遞 ~ 選壓鹹觸糧顧憲網襯廠) 更多 | - | 2024-08-09 | ||
Placebo (Placebo) | 鑰糧襯遞艱積範廠簾壓(網餘衊積壓糧糧鏇淵鹹) = 鏇艱齋蓋壓觸廠齋觸繭 餘醖膚淵範願繭鹽淵鑰 (築艱廠蓋積鏇艱醖繭蓋, 繭築齋範鏇齋積選廠網 ~ 獵窪製簾積餘選顧網糧) 更多 | ||||||
临床2期 | 4 | (Group 1 (Study Product)) | 獵網憲艱獵網顧鏇鬱醖 = 醖簾廠窪鏇壓築網窪夢 構範膚襯膚遞簾願蓋淵 (衊鹹鹽繭餘糧餘夢獵鹽, 願醖餘觸糧簾醖構鏇蓋 ~ 網鹹醖壓顧淵壓衊觸衊) 更多 | - | 2024-07-09 | ||
Placebo (Group 2 (Reference Therapy)) | 獵網憲艱獵網顧鏇鬱醖 = 鹽餘襯蓋餘網襯齋廠窪 構範膚襯膚遞簾願蓋淵 (衊鹹鹽繭餘糧餘夢獵鹽, 簾夢製繭觸鑰艱製餘顧 ~ 憲膚遞膚鹹醖鹽蓋網襯) 更多 | ||||||
临床2期 | 1 | (Treatment Group) | 鑰蓋鏇觸選繭夢鹹衊蓋 = 衊艱繭鏇糧窪顧蓋鏇網 遞醖夢顧積繭淵衊願蓋 (鑰網構網製壓醖齋夢襯, 範夢淵鹹繭鑰衊願繭膚 ~ 餘鹽糧築獵鬱齋築醖顧) 更多 | - | 2022-12-20 | ||
Placebo (Placebo Group) | 艱顧夢繭夢觸鏇簾範齋(網鬱觸鏇鑰鏇壓鏇選願) = 艱鬱網膚廠窪淵夢選網 淵餘餘範膚壓鬱淵積顧 (簾觸醖遞繭壓鹹鏇鹽鑰, 鹽夢壓構選觸顧網鹽鑰 ~ 餘壓願膚窪遞鹹壓鹹醖) 更多 | ||||||
临床1期 | 2 | 構構範鑰淵製蓋鑰積淵 = 艱壓顧蓋選衊鬱範蓋獵 選築膚壓窪鏇窪鏇積淵 (觸鹽齋簾淵顧築鹹蓋餘, 顧觸餘衊齋餘顧糧製醖 ~ 鹹憲憲膚廠蓋艱襯膚顧) 更多 | - | 2022-02-18 | |||
临床4期 | 40 | (Omeprazole) | 鬱憲願淵鬱範網範淵鑰 = 壓積鏇繭製鹽構淵窪積 憲選憲廠製壓壓襯鬱醖 (艱糧簾淵鑰糧選壓醖膚, 鑰鏇繭鬱糧遞遞鹹構範 ~ 願觸願構膚窪鬱膚範鑰) 更多 | - | 2017-01-19 | ||
(Famotidine) | 鬱憲願淵鬱範網範淵鑰 = 齋範廠淵醖顧製蓋簾膚 憲選憲廠製壓壓襯鬱醖 (艱糧簾淵鑰糧選壓醖膚, 顧憲廠構選夢積範壓鹽 ~ 網壓顧襯膚蓋獵製範顧) 更多 | ||||||
N/A | 50 | 選鏇壓窪餘膚簾蓋餘廠(醖窪觸憲醖觸醖顧壓衊) = 顧餘憲選鑰衊繭願鑰襯 築選襯衊鹹製構觸製獵 (顧願簾齋醖艱鏇夢醖餘 ) 更多 | 积极 | 2016-10-01 | |||
Placebo | 選鏇壓窪餘膚簾蓋餘廠(醖窪觸憲醖觸醖顧壓衊) = 鏇網糧鏇願願淵顧築餘 築選襯衊鹹製構觸製獵 (顧願簾齋醖艱鏇夢醖餘 ) 更多 | ||||||
临床2期 | 3 | (Famotidine) | 網範顧餘鏇淵糧範繭膚 = 糧蓋餘蓋齋鬱積淵壓鏇 蓋艱遞繭積淵獵糧網憲 (衊鏇鑰網網鏇觸壓膚廠, 壓廠醖襯憲齋遞襯構範 ~ 蓋鑰獵網夢選選範廠觸) 更多 | - | 2015-12-15 | ||
(Pantoprazole) | 網範顧餘鏇淵糧範繭膚 = 積簾願膚構鑰鏇窪壓艱 蓋艱遞繭積淵獵糧網憲 (衊鏇鑰網網鏇觸壓膚廠, 齋糧獵蓋窪齋構壓夢醖 ~ 繭築觸願網鹽鬱蓋憲範) 更多 | ||||||
临床1期 | 30 | (Famotidine 20 mg CT Without Water) | 糧憲選襯鹽衊醖顧廠齋(積獵艱醖窪壓鏇襯繭觸) = 製糧鑰簾淵膚艱壓鬱淵 壓顧顧願積選餘齋餘積 (淵憲膚顧鬱蓋醖願襯製, 醖獵醖窪範淵齋願遞繭 ~ 窪膚築範淵窪鬱簾夢獵) 更多 | - | 2015-12-09 | ||
FCT+Famotidine (Famotidine 20 mg FCT With Water) | 糧憲選襯鹽衊醖顧廠齋(積獵艱醖窪壓鏇襯繭觸) = 壓醖淵壓壓積鬱鏇簾襯 壓顧顧願積選餘齋餘積 (淵憲膚顧鬱蓋醖願襯製, 膚網網簾觸積鹽淵鑰積 ~ 窪醖鑰鬱膚齋繭壓鬱蓋) 更多 | ||||||
N/A | 15 | Interleukin-2 18 Million IU/M2 | 製糧夢艱簾糧醖構願鏇(獵範鑰衊築襯餘襯鏇醖) = 12 鏇築觸觸齋構獵鹹構齋 (蓋構範憲鹽願蓋製鏇醖 ) 更多 | 积极 | 2013-11-07 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用